Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Highlights of ASH in CLL

John Gribben and Stephan Stilgenbauer • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma 2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort 1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy 1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Stephan Stilgenbauer

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials 2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
Acquired mutations associated with resistance to BTKi in patients with CLL 2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12 2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL 2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL 2:08
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
Jennifer Woyach • 8 Dec 2025
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314 2:54
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals